ClinicalTrials.gg
RecruitingNCT02143830RAFAUpdated Nov 12, 2025

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

A Phase 2 interventional study of Busulfan and Cyclophosphamide in Fanconi Anemia, Severe Marrow Failure and Myelodysplastic Syndrome (MDS), sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 3 sites in United States. Open to participants aged 3 Months and older. Per ClinicalTrials.gov, last updated 2025-11-12.

Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 2, Interventional, and Treatment

How we know · 8 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
3 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies testing cyclophosphamide in Fanconi Anemia — 2 open to participants now, 2 under way, none of them phase 3. Cyclophosphamide · Fanconi Anemia.

Planned enrollment
2nd of 14
70 · median 28
Started
2014
the only one that year
Phase 2
7 of 16
2 open now
Registered
14th of 16
by date
Lead sponsor
1 of 16
Children's Hospital Medical Center, Cincinnati

Among the 16 studies testing cyclophosphamide in Fanconi Anemia, this one is the 2nd largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2014, is one of 7 in phase 2, and was the 14th registered.

Fanconi Anemia

95 studies on the registry are indexed under Fanconi Anemia; 20 are open to participants now.

Browse Fanconi Anemia studies →

Open to participants now

2 of the 16 studies testing cyclophosphamide in Fanconi Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 15 Fanconi Anemia studies recruiting now, 8 (53%) set no upper age limit and 4 (27%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 3 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing cyclophosphamide in Fanconi Anemia, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi Anemia (FA). Patients will undergo a transplant utilizing mis-matched related or matched unrelated donors following a preparative regimen of busulfan, fludarabine, anti-thymocyte globulin and cyclophosphamide.

Read the detailed description

The trial proposed is a three arm phase II treatment protocol designed to investigate the safety and efficacy of risk-adjusted chemotherapy-based cytoreductive regimen plus a CD34+ selected T-cell depleted peripheral blood stem cell (PBSC) stem cell transplant for the treatment of patients with Fanconi anemia and severe hematologic disease. Candidates for this trial will include patients with Fanconi anemia presenting with severe marrow failure (transfusion dependent) or myelodysplastic syndrome, or acute myelogenous leukemia for whom an allogeneic stem cell transplant is indicated.

03

Conditions studied

  • Fanconi Anemia
  • Severe Marrow Failure
  • Myelodysplastic Syndrome (MDS)
  • Acute Myelogenous Leukemia (AML)

Keywords

  • marrow aplasia
  • cytopenia
  • myelodysplasia
  • AML
  • bone marrow transplant
  • cytoreductive regimen
  • T-cell reduction
04

Who can participate

Ages eligible
3 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have a diagnosis of Fanconi anemia
  • Patients must have one of the following hematologic diagnoses:

    1. Severe Aplastic Anemia (SAA), with bone marrow cellularity of \<25% OR Severe Isolated Single Lineage Cytopenia and at least one of the following features:

      1. count \<20 x 109/L or platelet transfusion dependence*
      2. ANC \<1000 x 109/L
      3. \<8 gm/dl or red cell transfusion dependence*
    2. Myelodysplastic Syndrome (MDS) (based on WHO or IPSS Classification
    3. Acute Myelogenous Leukemia (untreated, in remission or with or relapsed disease)
  • Donors will be either human leukocyte antigen (HLA) compatible unrelated or HLA-genotypically matched related donors (no fully matched sibling donor).
  • Patients and donors may be of either gender or any ethnic background.
  • Patients must have a adult, or Lansky pediatric performance scale status > 70%.
  • Patients must have adequate physical function measured by:

    1. Cardiac: asymptomatic or if symptomatic then 1) (LVEF) at rest must be > 50% and must improve with exercise or 2) Shortening Fraction > 29%
    2. Hepatic: \< 5 x (ULN) (ALT) and \< 2.0 mg/dl total serum .
    3. Renal: serum creatinine \<1.5 mg/dl or if serum creatinine is outside the normal range, then > 50 ml/min/1.73 m2
    4. Pulmonary: asymptomatic or if symptomatic, DLCO > 50% of predicted
  • Each patient must be willing to participate as a research subject and must sign an form.
  • Female patients and donors must not be pregnant or breastfeeding at the time of signing consent. Women must be willing to undergo a pregnancy test prior to transplant and avoid becoming pregnant while on study.

Exclusion criteria

Exclusion Criteria:

  • Active CNS leukemia
  • Female patients who are pregnant (positive serum or urine HCG) or breast-feeding.
  • Active uncontrolled viral, bacterial or fungal infection
  • Patient seropositive for -I/II; HTLV -I/II
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Arm A: Good Risk Patients

    Patients 18 years old or younger with marrow aplasia or single lineage cytopenias will be receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days), as used in our most current study that led to \> 90% survival rates . Busulfan pharmacokinetics will not be used. All patients will receive rabbit ATG (4 doses x 4 days) prior to and granulocyte-colony stimulating factor (G-CSF) after transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells for all patients will be peripheral blood stem cells mobilized by treatment of the donor with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). Enrollment on this arm will include up to 50 patients.

    Drug: Busulfan · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: rabbit ATG · Drug: G-CSF · Biological: Peripheral blood stem cell

  • Experimental
    Arm B: Intermediate Risk Patients

    Patients 18 years old or younger with MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). Busulfan pharmacokinetics will be used in this arm, as the dose of busulfan is higher. All patients will receive rabbit ATG (thymoglobulin) (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for prophylaxis against GVHD. The source of the stem cells for all patients will be peripheral blood stem cells induced and mobilized by treatment of the donor. T-cell will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). The maximum number of patients enrolled in this arm will be 10.

    Drug: Busulfan · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: rabbit ATG · Drug: G-CSF · Biological: Peripheral blood stem cell

  • Experimental
    Arm C: High Risk Patients

    Patients 19 years old or older with marrow aplasia or MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). In this study, we will test whether outcomes can be improved, yet engraftment maintained, with a slightly reduced dose of busulfan. Patients will receive rabbit ATG (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells will be peripheral blood stem cells collected from donors treated with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). The maximum number of patients enrolled will be 10.

    Drug: Busulfan · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: rabbit ATG · Drug: G-CSF · Biological: Peripheral blood stem cell

Interventions

  • A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A). A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control. A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity.

    Also known as: Myleran, Busulfex IV

  • Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.

    Also known as: Cytoxan

  • Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.

    Also known as: Fludara

  • DrugThymoglobulinStudies of ThymoglobulinThymoglobulin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment.

    Also known as: thymoglobulin

  • DrugGranulocyte Colony-Stimulating FactorStudies of Granulocyte Colony-Stimulating FactorGranulocyte Colony-Stimulating Factor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All patients will also receive G-CSF post-transplant to foster engraftment.

    Also known as: Granulocyte colony-stimulating factor, filgrastim, neupogen

  • The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).

06

What researchers measure

Primary outcomes

  1. Graft Failure or Rejection

    Primary non-engraftment is diagnosed when the patient fails to achieve an ANC \>=500/mm3 at any time in the first 28 days post-transplant. If (1) after achievement of an absolute neutrophil count (ANC) \>=500/mm3, the ANC declines to \<500/mm3 for more than 3 consecutive days in the absence of relapse, or, (2) there is absence of donor cells in the marrow and/or blood as demonstrated by chimerism assay in the absence of relapse, a diagnosis of secondary graft failure is made. The patient is not evaluable for graft failure or rejection if recurrence of host MDS is detected concurrently.

    Time frame: 5 years

Secondary outcomes

  1. Post-transplant severe morbidity and mortality

    The occurrence of severe post-transplant regimen-related severe morbidity (grade IV toxicity) and/or mortality will be the second endpoint of this study. In the context of the agents or agent-combination used for cytoreduction used, particular attention will be given to toxicity involving (1) the liver, (2) the lungs, (3) the oral mucosa and gastrointestinal tract, and (4) the central nervous system.

    Time frame: 2 years post-transplant

Other outcomes

  1. Graft Versus Host Disease

    Patients will be observed for acute and/or chronic graft versus host disease (GvHD). Standard clinical criteria for the grading of acute and chronic GvHD will be done according to IBMTR guidelines.

    Time frame: One year

  2. Leukemic Relapse

    For patients with MDS or AML, relapse will be analyzed as to type and genetic origin of the MDS/leukemic cells.

    Time frame: 5 years

  3. Secondary malignancies

    Patients will be followed for 5 years through annual contact with their treatment center in order to track the risk of developing a secondary malignancy.

    Time frame: 5 years

07

Study locations

2 of 3 sites recruiting
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10174, United States
    Completed

    Not enrolling at this site.

  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
    Recruiting
    • Parinda Mehta, MD · Principal investigator
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
    Recruiting
    • Sheri Ballard · Contactsballard@fredhutch.org · 206-667-4222
    • K. Scott Baker, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Dec 2026 and a completion of Dec 2028. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2014
First posted
May 21, 2014
Start
Apr 2014
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2028
Last update
Nov 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02143830
Responsible party
Sponsor
First posted
May 21, 2014
Start date
Apr 2014
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 12, 2025

Study contacts

Jamie Wilhelm
Contact
Jamie.Wilhelm@cchmc.org
(513)803-1102
Sara Loveless, RN
Contact
Sara.Loveless@cchmc.org
(513)803-7656
Parinda Mehta, MD
principal investigator · CCHMC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Busulfan · Cyclophosphamide · Fludarabine

Start the discussion